Loading...
Loading...
Genomic Health, Inc.
GHDX today announced that the peer-reviewed journal PLoS ONE published positive results from its groundbreaking clinical outcomes study for biomarker discovery applying Next Generation Sequencing (NGS) for whole transcriptome profiling of archival formalin-fixed paraffin embedded (FFPE) tumor specimens.
Results demonstrated that Genomic Health's proprietary whole transcriptome RNA-Seq technology successfully rediscovered validated genes used in the Oncotype DX® breast cancer test that previously had been identified by RT-PCR, and discovered more than two thousand additional candidate biomarkers for future clinical research and development.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in